[go: up one dir, main page]

AU2003284899A8 - Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake - Google Patents

Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake

Info

Publication number
AU2003284899A8
AU2003284899A8 AU2003284899A AU2003284899A AU2003284899A8 AU 2003284899 A8 AU2003284899 A8 AU 2003284899A8 AU 2003284899 A AU2003284899 A AU 2003284899A AU 2003284899 A AU2003284899 A AU 2003284899A AU 2003284899 A8 AU2003284899 A8 AU 2003284899A8
Authority
AU
Australia
Prior art keywords
blockade
prefrontal
adjunctive
reuptake
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003284899A
Other versions
AU2003284899A1 (en
Inventor
Graham V Williams
Stacy A Castner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MIICRO Inc
Original Assignee
MIICRO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MIICRO Inc filed Critical MIICRO Inc
Publication of AU2003284899A8 publication Critical patent/AU2003284899A8/en
Publication of AU2003284899A1 publication Critical patent/AU2003284899A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003284899A 2002-10-29 2003-10-24 Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake Abandoned AU2003284899A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42198002P 2002-10-29 2002-10-29
US60/421,980 2002-10-29
PCT/US2003/033730 WO2004039322A2 (en) 2002-10-29 2003-10-24 Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake

Publications (2)

Publication Number Publication Date
AU2003284899A8 true AU2003284899A8 (en) 2004-05-25
AU2003284899A1 AU2003284899A1 (en) 2004-05-25

Family

ID=32230298

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003284899A Abandoned AU2003284899A1 (en) 2002-10-29 2003-10-24 Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake

Country Status (2)

Country Link
AU (1) AU2003284899A1 (en)
WO (1) WO2004039322A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2397981C (en) 2000-03-06 2010-12-21 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
ATE466014T1 (en) 2001-12-28 2010-05-15 Acadia Pharm Inc SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
MXPA04012893A (en) 2002-06-24 2005-03-31 Acadia Pharm Inc N-substituted piperidine derivatives as serotonin receptor agents.
US7601740B2 (en) 2003-01-16 2009-10-13 Acadia Pharmaceuticals, Inc. Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
DK1794126T3 (en) 2004-09-27 2013-06-24 Acadia Pharm Inc Crystalline form of N - (- 4-fluorobenzyl) -N- (1-methylpiperidin-4-yl) -N '- (4- (2-methylpropyloxy) phenylmethyl) carbamide hemitartrate
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
ES2423485T3 (en) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Associations of 5-HT2A inverse agonists and antagonists with antipsychotics
JP2011519873A (en) * 2008-05-07 2011-07-14 ハー・ルンドベック・アクチエゼルスカベット How to treat cognitive deficits
ES2890492T3 (en) 2015-07-20 2022-01-20 Acadia Pharm Inc Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic Form C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
CN110087641B (en) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 Transdermal therapeutic systems containing asenapine and polysiloxane or polyisobutylene
KR102506333B1 (en) 2016-12-20 2023-03-06 에르테에스 로만 테라피-시스테메 아게 Transdermal absorption treatment system containing asenapine
EP3615028A1 (en) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CN112704672A (en) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 Transdermal therapeutic system comprising asenapine
CN112533593A (en) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 Transdermal therapeutic system comprising asenapine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent

Also Published As

Publication number Publication date
AU2003284899A1 (en) 2004-05-25
WO2004039322A2 (en) 2004-05-13
WO2004039322A3 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
AU2003284899A8 (en) Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
ZA200309627B (en) Compounds for the treatment of metabolic disorders
GB2349570B (en) Compositions for treatment of disorders of the oesophagus associated with reflux
IL161509A0 (en) Therapeutic quinolone compounds with 5-ht-antogonistic properties
HUP0400131A3 (en) Photodynamic therapy lamp
AU2003220553A1 (en) Combination therapy for the treatment of conditions with pathogenic inflammatory components
PL370071A1 (en) Therapeutic quinoline compounds with 5-ht-antagonistic properties
IL156567A0 (en) Triazolopyridines as anti-inflammatory agents
PL373626A1 (en) Treatment for central nervous system disorders
EP1448205A4 (en) Combinations for the treatment of immunoinflammatory disorders
HUP0500424A2 (en) Combination therapy for the treatment of cancer
IL160143A0 (en) Novel imidazopyridine compounds with therapeutic effect
WO2002073196A3 (en) Individualization of therapy with antipsychotics
HU0103986D0 (en) New compounds with therapeutic effect
PT1492501E (en) Methods of using lamellar bodies for therapeutic purposes
IL163871A0 (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
IL160852A0 (en) Pharmaceutical compositions for the treatment of urinary disorders
AU2002254947A1 (en) Kappa opiate agonists for the treatment of bladder diseases
AU2001287218A1 (en) The use of melatonin for induction of general anesthesia
AU2003220338A8 (en) Photosensitizers for photodynamic therapy of microbial infections
HRP20041159A2 (en) Combination for the treatment of airway disorders
AU2002339699A8 (en) Use of obg3 for promoting central nervous system remyelination
ITMI20041923A1 (en) LIGHT SOURCE FOR PHOTODYNAMIC THERAPY WITH IMPROVED CHARACTERISTICS FOR THE IMPLEMENTATION OF THERAPEUTIC PROTOCOLS
AU2002342488A1 (en) Individualization of therapy with anesthetics
TW525622U (en) Dual track trolley

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase